 8. Receipt of treatment with immunotherapy including interferons, interleukins, immunoconjugates, biological therapies including monoclonal antibodies or other engineered proteins, targeted small molecules including but not limited to kinase inhibitors, hormonal therapies except for gonadotropin releasing hormone agonistsantagonists for prostate cancer which may be continued while on study within 3 weeks of scheduled dosing day 1. 